Login to Your Account

Amarin Jumps on Positive Phase III Fish Oil Pill Data

By Donna Young

Tuesday, November 30, 2010
Shares of Amarin Corp. plc skyrocketed as high as 67 percent Monday after the biotech reported that its prescription grade omega-3 fatty acid drug AMR101 (ethyl icosapentate) not only lowered triglycerides in patients with high levels during a pivotal Phase III study, but the drug did not increase low-density lipoprotein cholesterol (LDL-C) – a claim GlaxoSmithKline plc's Lovaza (omega-3-acid ethyl esters) cannot make. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription